Recent studies on doxorubicin and its analogues

Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity

Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX's action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.

Strategies for Covalent Attachment of Doxorubicin to Poly(PEG-Lys), a New Water-Soluble Poly(ether urethane

Poly(PEG-Lys) is a new, water soluble poly(ether urethane) that has shown promise as an injectable drug carrier. To evaluate the possible use of this drug carrier in chemotherapy, three different approaches for the covalent attachment of doxorubicin to the pendent carboxylic acid groups of poly(PEG- Lys) were developed. In one approach, the pendent carboxylic acid groups of poly(PEG-Lys) were converted to N-hydroxysuccinimide active esters, which spontaneously formed hydrolytically stable amide bonds upon reaction with the amino group located on the daunosamine ring of doxorubicin. The amount of amide-bound doxorubicin was about 7.3 mg/100 mg of conjugate. In a second approach, the degradable hydrazone linkage was formed by reaction of the polymeric hydrazide derivative of poly(PEG-Lys), designated as poly(PEG-Lys hydrazide), with the 13-keto group of doxorubicin. After purification, the amount of carrier-bound doxorubicin was 13.5 mg/100 mg of conjugate. In the third approach, the conjugation of doxorubicin via secondary amine linkages was explored. In this approach, the aldehyde derivative of poly(PEG Lys), desig nated as poly(PEG-Lys-aldehyde), was reacted with doxorubicin, followed by re duction of the intermediate Schiff base with sodium cyanoborohydride. After extensive purification of the carrier, the amount of bound doxorubicin was 10 mg/100 mg of conjugate. All conjugates were characterized by UV/Vis and FTIR spectroscopy and by thin layer chromatography. The conjugates were free of de tectable contamination by unbound drug.

An enhanced ability for transforming adriamycin into a noncytotoxic form in a multidrug-resistant cell line (LZ-8)

Multidrug-resistant LZ-8 cells are 9000-fold more resistant to Adriamycin (ADRM) exposure than wild-type V79 cells. To understand more about the mechanisms producing such high level resistance, we tested whether LZ-8 cells inactivate ADRM toxicity to a greater extent than wild-type V79 cells. ADRM was recovered from (1) culture media of wild-type V79 and ADRM-resistant LZ-8 cells; (2) V79 and LZ-8 cells; and (3) LZ-8 cell plasma membrane, and the cytotoxicity was determined by treating V79 cells for 1 hr with a known concentration of the recovered ADRM. ADRM obtained from LZ-8 cells or its culture medium exhibited less cytotoxicity than that recovered from V79 cells or its culture medium. ADRM extracted from LZ-8 cell plasma membrane was noncytotoxic. HPLC analysis revealed that the extracted ADRM was structurally changed compared to stock ADRM. The retention time in the column was 7 min for stock ADRM, and 23 min for the recovered ADRM. Thus, LZ-8 cells have an increased ability to transform ADRM into a noncytotoxic form compared to wild-type V79 cells. This transformation involves structural conversion into a previously unidentified ADRM metabolite. The greatly increased survival of LZ-8 cells compared to V79 cells after ADRM treatment is due to at least two mechanisms: (1) an enhanced ability to inactivate the cytotoxicity of ADRM, and (2) increased drug efflux resulting from the amplification and overexpression of the pgp 1 gene in these cells. Our results suggest the possibility that P-glycoprotein participates in drug binding/inactivation in addition to serving as a drug efflux pump.

Bis-daunomycin hydrazones: interactions with DNA

A series of bis-daunomycin hydrazones were synthesised from diester diamide linking groups derived from alpha,omega-dicarboxylic acids. All members of the series bis-intercalated into DNA, as evidenced by doubling of the lengthening of rod-like DNA compared to daunomycin, and by a 1000-5000 fold slower dissociation from DNA than daunomycin under detergent sequestration conditions. The bis-hydrazones exhibited neighbour exclusion, and occupied 6 bp under saturating conditions of drug. A unique DNA sequence specificity was apparent from transcriptional footprinting of 100 bp of DNA, with the greatest preference for 5'-CACA sites.

Biophysical chemistry of the daunomycin-DNA interaction

Daunomycin (daunorubicin) is a potent anticancer antibiotic that binds to DNA by the process of intercalation. Fundamental aspects of the physical chemistry of the daunomycin-DNA interaction are reviewed here, including the thermodynamics and kinetics of the binding reaction, and recent work that indicates that daunomycin binds preferentially to certain sites along the DNA lattice. The solution studies reviewed here combine with recent theoretical and crystallographic investigations to make the daunomycin-DNA interaction one of the best-characterized intercalation reactions. The molecular interactions that stabilize the daunomycin-DNA complex, and which contribute to its sequence preference, are discussed.

The pharmacokinetics of polymer-bound adriamycin

Adriamycin (ADR) covalently bound to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers via biodegradable (Gly-Phe-Leu-Gly) oligopeptide sequences shows antitumour activity against model tumours in vivo. In this study we have examined the distribution of ADR bound to such HPMA copolymers following intravenous administration to mice (ADR concentration 5 mg/kg). An established fluorimetric HPLC method was used to measure levels of free ADR in plasma and tissue samples, and a new technique was developed to quantitate levels of polymer-bound anthracycline. The high initial levels of free ADR in plasma observed following administration of free drug were absent in the case of polymer-bound ADR, and the subsequently high levels of free ADR seen in other tissues were also abolished. In contrast, the circulating half-life of HPMA copolymer-ADR was approximately 15 times longer than that of the free drug. The initial peak level of free ADR in the heart was reduced 100-fold following administration of drug-conjugate. These alterations in pharmacokinetics may account for the decreased toxicity and improved efficacy reported previously.

Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells

The present study was designed to test the in vitro efficacy for human ovarian cancer cells of daunorubicin (DNR) conjugated to a monoclonal antibody (OC125). The OC125 antibody specifically binds to the antigenic protein CA125 from human ovarian carcinoma. New analogs of DNR containing various linker groups were conjugated to mouse monoclonal anti-CA125 antibody (DNR-OC125); nonspecific murine IgG1 (DNR-IgG1); or bovine serum albumin (DNR-BSA). The DNR-protein conjugates were all stable for several days in neutral solutions at room temperature. The DNR-OC125 conjugates selectively killed dividing cell populations but not nondividing cell populations of two human ovarian cancer cell lines (SK-OV-3 or OVCAR-3) that express the CA125 antigen. Equivalent concentrations of DNR-IgG1 or DNR-BSA conjugates were neither toxic to the dividing nor the nondividing populations of SK-OV-3 or OVCAR-3 cells. Only those DNR-protein conjugates linked to OC125 were cytotoxic to dividing cell populations of both cell lines. This indicates that cytotoxicity is dependent on OC125 antibody-CA125 antigen binding which concentrates DNR on the ovarian cancer cells. We advance the hypothesis that following antibody-antigen binding, DNR is released from the conjugate and it intercalates in DNA by a mechanism similar to that of the unmodified DNR. The new DNR-OC125 conjugate may be useful for delivering DNR to ovarian tumors that express the CA125 antigen because the drug-antibody conjugates (1) retain the cytotoxic characteristics of the unmodified drug: (2) specifically kill the human ovarian cancer cells that express the CA125 antigen; and (3) are completely stable for days in neutral solutions at room temperature.